Blood pressure (BP), heart rate (HR), and urinary norepinephrine excretion were 7 followed up for 3 months. Plasma and renal tissue concentrations of norepinephrine and 8 plasma renin activity were measured 3 months after the procedure. The RDN was 9
There is no report concerning the effects of RF-RDN on BP in hypertensive animals such 4 as spontaneously hypertensive rats (SHR). Furthermore, technical details of RF-RDN 5 in small animals such as rats have not been reported. Because the RF-RDN is applied 6 to the patients with resistant hypertension, it seems to be quite important to reveal the 7 precise effects of RF-RDN on BP in SHR. 8 Therefore, this study aimed to investigate the anti-hypertensive effect of RF-RDN 9 in a rat model of hypertension, SHR. 10 1
Material and Methods 2 Animals 3
Male SHR and their normotensive controls, Wistar-Kyoto rats (WKY) were 4 purchased from Japan Charles River (Kanagawa, Japan) at 8 weeks of age. All rats were 5 housed in an animal facility with a 12-hour light/dark cycle. They received standard 6 chow (NMF; Oriental Yeast Co., Ltd., Tokyo, Japan) and drinking water ad libitum. All 7 experimental procedures were performed in accordance with institutional guidelines for 8 animal research approved by the Experimental Animal Committee at University of 9
Tsukuba. 10 
Experimental Protocol 11
To evaluate the anti-hypertensive effect of RF-RDN, all rats were followed up for 3 12 months after treatments: bilateral RF-RDN (SHR-RDN, n=8; WKY-RDN, n=8) and sham 13 operation (SHR-Sham, n=8; WKY-Sham, n=8). The RF-RDN and sham operation were 14 performed at 12 weeks of age, as described below. Blood pressure (BP) and heart rate 15 1 Results 2
Procedural Data 3
The RF-RDN was performed to a similar extent in the WKY-RDN and SHR-RDN 4 (Table 1 ). There were no differences in mean RF power and total number, duration, and 5 energy of RF application. The mean decrease in local impedance after each RF 6 application was also comparable between the two groups. The local impedance was not 7 different among the 4 groups (WKY-Sham, WKY-RDN, SHR-Sham, and SHR-RDN). 8
Effects of RF-RDN on Blood Pressure 9
The RF-RDN for SHR significantly restrained a spontaneous rise in systolic and 10 diastolic BP after the 3 months follow-up ( Figure 1A and 1B). The SHR-RDN 11 demonstrated a lower spontaneous rise in systolic BP than the SHR-Sham (21±18% 12 increase from 165±9 to 197±20 mmHg vs. 46±12% increase from 158±8 to 230±14 mmHg, 13 p=0.01). The SHR-RDN also demonstrated a lower spontaneous rise in diastolic BP than 14 the SHR-Sham (28±13% increase from 120±7 to 154±13 mmHg vs. 55±27% increase from 15 117±9 to 179±23 mmHg, p=0.04). 16
The BP of WKY, however, was not affected by the RF-RDN after the 3 months 17 follow-up ( Figure 1A and 1B 345±34 ng/day, p=0.60), and 3 months (372±64 vs. 342±35 ng/day, p=0.64). 5
Effects of RF-RDN on Urine Output 6
Urine output for 24 hours was not affected by the RF-RDN in the WKY and SHR 7 during the 3-month follow-up period (Figure 3) . The 24-hour urine output was not 8 different between the SHR-RDN and SHR-Sham at baseline (7.4±1.6 vs. 7.1±1.1 mL/day, 9 p=0.99), 1 month (7.7±1.5 vs. 7.6±1.8 mL/day, p=1.00), and 3 months (8.4±1.4 vs. 7.8±1.8 10 mL/day, p=0.97), or between the WKY-RDN and WKY-Sham at baseline (13.3±2.4 vs. 11 13.4±3.7 mL/day, p=1.00), 1 month (15.5±3.9 vs. 15.5±2.6 mL/day, p=1.00), and 3 months 12 (15.9±4.0 vs. 14.7±3.4 mL/day, p=0.84). 13 However, there was a difference in 24-hour urine output between the SHR and 14 WKY. The SHR-Sham demonstrated a lower 24-hour urine output than the WKY-Sham 15 at baseline (7.1±1.1 vs. 13.4±3.7 mL/day, p<0.01), 1 month (7.6±1.8 vs. 15.5±2.6 mL/day, 16 p<0.01), and 3 months (7.8±1.8 vs. 14.7±3.4 mL/day, p0.01). The SHR-RDN also 17 demonstrated a lower 24-hour urine output than the WKY-RDN at baseline (7.4±1.6 vs. 18 13.3±2.4 mL/day, p<0.01), 1 month (7.7±1.5 vs. 15.5±3.9 mL/day, p<0.01), and 3 months 19 (8.4±1.4 vs. 15.9±4.0 mL/day, p<0.01). 20
Effects of RF-RDN on Urinary Norepinephrine 21
The 24-hour urinary norepinephrine excretion was not affected by the RF-RDN in 22 the WKY and SHR during the 3-month follow-up period (Figure 4) p<0.01; Figure 7) . The SHR-Sham demonstrated higher renal norepinephrine content 7 than the WKY-Sham (302±41 vs. 203±33 ng/g kidney, p<0.01); however, there was no 8 difference between the SHR-RDN and WKY-RDN (159±44 vs. 145±26 ng/g kidney, 9
p=0.84). The issue of selecting responders to RDN is problematic and controversial. Our 10 data might suggest that the RF-RDN is also effective for hypertension associated with 11 obesity and chronic kidney disease, which also demonstrates high renin and enhanced 12 systemic sympathetic activity. Obesity and chronic kidney disease as well as high decreased approximately 40 Ω after each RF application, which might provide a useful 21 readout for the effective RF-RDN, similar to an autonomic response to electrical 22 stimulation of renal nerves (Chinushi et al. 2013 ). In addition, the RF-RDN might be 23 effective when the RF application is repeated until a number of RF applications withduration of more than 20 sec reaches three times for each renal artery as described in the 1 methods section. 2
The RF-RDN procedure exhibited excellent safety under the temperature control 3 mode with a limited maximum power output. Repeated RF applications guided by a 4 decrease in local impedance and sufficient RF duration might be required for the 5 effective RF-RDN. 6
Limitations 7
The mechanisms of regulating BP include not only the sympathetic nerve system 8 and renin-angiotensin system but also the carotid baroreflex system (Lohmeier et al. anti-hypertensive effect of RF-RDN seemed to be mediated by a reduction of enhanced 7 plasma renin activity. Technical aspects of RF-RDN were also examined in detail to 8 provide safety and efficacy for replication. This study provides a novel insight into the 9 use of RF-RDN, which is a clinically expanding treatment for the resistant hypertension. 10
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